The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...

Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...

If you have been diagnosed with metastatic breast cancer, resources like support groups, counseling, financial assistance, and online communities can help.

DATROWAY Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer ...

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.

AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo.

DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or ...

It’s been months in the making, but now the new resource is available for those battling the treatable, but incurable form of ...

Allegheny Health Network's Cancer Institute announced Wednesday the launch of a pilot program addressing the mental health ...

The FDA has granted fast track designation to emiltatug ledadotin for advanced or metastatic breast cancer treatment, as ...